Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Manidipine for Calcific Aortic Valve Disease
NCT07091136Phase 2Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of manidipine in calcific aortic valve disease (CAVD) (3 arms). Primary endpoint: Change in Aortic Valve Calcium Score at 12 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
manidipine
03
Conditions
calcific aortic valve disease (CAVD)
Beyond the preview
Go deeper on NCT07091136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07091136.